News
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. The price of Rivian stock is down 21% so far this month after multiple news seem to have unleashed another wave of negative momentum for the electric vehicle startup. On 5 January, a… Continue reading Rivian Stock Down 21% in January – Time to Buy RIVN Stock?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Pfizer (NYSE: PFE) stock is trading with a YTD loss this year after the strong outperformance in 2021. The stock is now down almost 9% from the 52-week highs. However, its drawdown from… Continue reading Pfizer Stock Price Forecast January 2022 – Time to Buy PFE Stock?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. ChainScore brings multi-chain credit data to de-risk DeFi on NEAR protocol, providing more use cases for the blockchain and motivating investors to buy NEAR Crypto market down by 0.89% over the last day… Continue reading NEAR Protocol Price Up by 16% – Time to Buy NEAR?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. The price of Palantir stock has kept declining in January following the weakness that started back in November when the company reported its financial results covering the third quarter of the 2021 fiscal… Continue reading Palantir Stock Down 9% in January – Time to Buy PLTR Stock?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Oasis Network trades in the green despite the bears engulfing the crypto market, prompting investors to buy ROSE The year 2022 begins on a stellar note for Oasis Network after recording impressive gains… Continue reading Oasis Network Price Up By 13% – Time To Buy ROSE Coin?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Shares of molecular diagnostics company Genedrive(LSE: GDR) are in the red today, currently trading at 31p at the time of writing. Genedrive shares have surged over 230% in the last month. Genedrive –… Continue reading Genedrive Share Forecast January 2022 – Time to Buy GDR?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Unless you’ve been living under a rock, you know that the free world is moving full-steam ahead towards cryptocurrencies. It’s exciting, perhaps frightening, and for most, an incredibly confusing financial instrument they don’t… Continue reading How to Easily Mine the Best Cryptocurrencies with StakeAdvisors
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. With the price of Cosmos currently outperforming most of the major altcoins in the past 24 hours, it sure looks like a good time to buy ATOM The Cosmos ecosystem is excited at… Continue reading Cosmos Price Up 5.83% – Time to Buy ATOM Coin?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Shares of American automotive and energy storage company (NASDAQ: PTRA) are in the green today after closing at $9.34 as of January 10th (19:59 EST). EV companies have always been a welcome addition… Continue reading Proterra Share Forecast January 2022 – Time to Buy PTRA?
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. Shares of London-based financial technology company Wise (LSE: WISE) are in the red today, after closing at £606.4 as of January 10th (17:51 GMT). Wise has a market share which is less than… Continue reading Wise Share Forecast January 2022 – Time to Buy WISE?
